153 related articles for article (PubMed ID: 22736295)
1. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
Nishikawa H; Tsudo M; Osaki Y
Oncol Rep; 2012 Sep; 28(3):835-40. PubMed ID: 22736295
[TBL] [Abstract][Full Text] [Related]
2. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy.
Chen TT; Chiu CF; Yang TY; Lin CC; Sargeant AM; Yeh SP; Liao YM; Bai LY
Leuk Res; 2015 Feb; 39(2):151-6. PubMed ID: 25524176
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy.
Salah-Eldin MA; Ebrahim MA; El-Sadda W
Ann Hematol; 2014 Nov; 93(11):1903-11. PubMed ID: 24951125
[TBL] [Abstract][Full Text] [Related]
6. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature.
Nooka A; Shenoy PJ; Sinha R; Lonial S; Flowers CR
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):379-84. PubMed ID: 21729690
[TBL] [Abstract][Full Text] [Related]
9. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
10. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
[TBL] [Abstract][Full Text] [Related]
11. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.
Ennishi D; Maeda Y; Niitsu N; Kojima M; Izutsu K; Takizawa J; Kusumoto S; Okamoto M; Yokoyama M; Takamatsu Y; Sunami K; Miyata A; Murayama K; Sakai A; Matsumoto M; Shinagawa K; Takaki A; Matsuo K; Kinoshita T; Tanimoto M
Blood; 2010 Dec; 116(24):5119-25. PubMed ID: 20823454
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy.
Nosotti L; D'Andrea M; Pitidis A; Pimpinelli F; Dessanti ML; Pisani F; Vignally P; Petti MC
Scand J Infect Dis; 2012 Jan; 44(1):70-3. PubMed ID: 21905952
[TBL] [Abstract][Full Text] [Related]
13. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
[TBL] [Abstract][Full Text] [Related]
14. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.
Huang YC; Liu CJ; Liu CY; Pai JT; Hong YC; Teng HW; Hsiao LT; Chao TC; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Yu YB; Tzeng CH
Ann Hematol; 2011 Oct; 90(10):1145-51. PubMed ID: 21647583
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
Besson C; Canioni D; Lepage E; Pol S; Morel P; Lederlin P; Van Hoof A; Tilly H; Gaulard P; Coiffier B; Gisselbrecht C; Brousse N; Reyes F; Hermine O;
J Clin Oncol; 2006 Feb; 24(6):953-60. PubMed ID: 16418500
[TBL] [Abstract][Full Text] [Related]
16. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.
Lee L; Crump M; Khor S; Hoch JS; Luo J; Bremner K; Krahn M; Hodgson DC
Br J Haematol; 2012 Aug; 158(4):481-8. PubMed ID: 22671571
[TBL] [Abstract][Full Text] [Related]
17. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H
Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062
[TBL] [Abstract][Full Text] [Related]
18. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma.
Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS
Ann Hematol; 2012 Sep; 91(9):1383-91. PubMed ID: 22526364
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index.
Chen YY; Huang CE; Liang FW; Lu CH; Chen PT; Lee KD; Chen CC
Cancer Epidemiol; 2015 Jun; 39(3):382-7. PubMed ID: 25899771
[TBL] [Abstract][Full Text] [Related]
20. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
